Management of Non-Productive Cough in ESRD Patients

Epidemiology and Risk Stratification

Peritoneal dialysis patients develop persistent cough significantly more frequently than hemodialysis patients (22% vs 7%), primarily due to increased intra-abdominal pressure from dialysate causing or worsening GERD 1, 2

The American Thoracic Society recommends assessing for signs of fluid overload: peripheral edema, abnormal lung sounds, elevated jugular venous pressure, as pulmonary edema is a common cause of cough in ESRD patients regardless of dialysis modality 1, 2
The European Respiratory Society suggests reviewing adequacy of dialysis and sodium restriction to prevent fluid overload 3

The American College of Chest Physicians recommends discontinuing ACE inhibitors if present; switching to angiotensin receptor blocker, as ACE inhibitors are used in 65% of PD patients and 55% of HD patients and can cause cough 2
The European Respiratory Society suggests intensifying dialysis if fluid overload is present, and implementing strict sodium and fluid restriction 3
The American Gastroenterological Association recommends initiating high-dose proton pump inhibitor therapy and implementing dietary modifications to treat GERD aggressively, especially in PD patients 4

The British Thoracic Society suggests considering dextromethorphan 30-60 mg for severe cough affecting quality of life, as it provides effective cough suppression 5

The European Respiratory Society reports that ESRD patients with pleural effusions have significantly worse outcomes: 6-month mortality 31%, 1-year mortality 46%, highlighting the importance of aggressive evaluation and management of respiratory symptoms in this population 3

Dextromethorphan is a central cough suppressant that has demonstrated efficacy for short-term symptomatic relief in patients with chronic bronchitis, providing effective cough suppression without significant renal elimination concerns, as recommended by the American Thoracic Society 6

The American College of Chest Physicians recommends avoiding ipratropium bromide or other anticholinergic agents without careful consideration, as elderly ESRD patients may be more susceptible to anticholinergic side effects 6
Over-the-counter combination cold medications should be avoided, as they have not been proven effective for cough suppression and may contain ingredients requiring dose adjustment in renal failure, according to the American Academy of Family Physicians 6

Cough typically resolves within 1-4 weeks of cessation of ACE inhibitors, though may take up to 3 months in some patients, and switching to an angiotensin receptor blocker is recommended if renin-angiotensin system blockade is still indicated, as suggested by the American Heart Association 7

The National Kidney Foundation recommends drug selection should prioritize non-renal excretion pathways to avoid accumulation and toxicity in ESRD patients 8
The National Kidney Foundation suggests avoiding nephrotoxic medications or combinations when possible, as ESRD patients are at higher risk for drug-induced acute kidney injury 8
Individualized decisions should be made to discontinue, introduce, or reintroduce medications based on renal versus non-renal excretion, potential for nephrotoxicity, strength of indications, and availability of suitable alternatives, as recommended by the National Kidney Foundation 8

The American Heart Association, as published in Circulation, recommends avoiding codeine and other opioid antitussives in ESRD patients due to significantly greater adverse effects, and instead reserve opioids only for severe cases unresponsive to dextromethorphan 9

The American Thoracic Society implies that for chronic bronchitis, Ipratropium bromide is the only inhaled anticholinergic recommended for cough suppression, regardless of renal function, although the article does not explicitly mention the society 9